Valneva’s Stock Awaits Two Critical Catalysts

While Valneva prepares to release its full-year 2025 financial results this Tuesday, investor focus is firmly fixed elsewhere. The upcoming Phase 3 data for its Lyme disease vaccine candidate, VLA15, holds the potential to fundamentally reshape the company’s future.

Financial Foundation Faces Near-Term Pressure

The market anticipates few surprises from the March 18th earnings report. Preliminary total revenue for 2025 showed a modest increase to €174.7 million. However, management has guided for a decline to between €155 million and €170 million in 2026, attributed to the scheduled expiration of third-party commercial agreements. The company’s organically growing travel vaccine business, which recently expanded by nine percent, is not expected to fully offset this short-term gap.

Liquid resources decreased over the course of the year, moving from €168.3 million down to €109.7 million. Despite this reduction, a successful debt refinancing operation has secured sufficient financial runway to continue funding its ongoing development programs.

The Billion-Euro Opportunity: VLA15

The company’s pipeline represents its most compelling story. VLA15 stands as the world’s only advanced clinical-stage Lyme disease vaccine candidate. Results from the Phase 3 trial, which enrolled nearly 9,500 participants, are anticipated in the first half of 2026. Should the data prove positive, development partner Pfizer intends to submit the vaccine for regulatory approval before the end of the year.

Should investors sell immediately? Or is it worth buying Valneva?

A successful outcome would transform Valneva from a niche player into a co-developer of a potential blockbuster vaccine, unlocking significant revenue streams through its partnership with Pfizer. The latter half of the year will then bring data for the next pipeline milestone: the Shigella vaccine candidate.

Shifting Sentiment Among Major Shareholders

A notable development occurred within the shareholder register just ahead of the earnings release. French public investment bank Bpifrance reduced its stake by approximately 1.1 million shares, bringing its voting rights down to 8.0%. Almost simultaneously, Caisse des dépôts et consignations increased its position—a transfer within the French public sector that leaves the overall state-backed ownership largely unchanged.

Valneva’s share price currently trades roughly 11% below its 52-week high of €5.16, though it has still advanced nearly 45% over the past twelve months. Technical analysis indicates a significantly oversold condition, with a Relative Strength Index (RSI) reading of 18.9. While the annual figures on March 18th will set the stage, the ultimate directional catalyst for the stock will be the clinical data readout for VLA15.